Condition: AML · MRD · Sponsor: Shanghai Tong Ren Hospital
This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia based on MRD results on day 14 of the first cycle.
This description comes directly from the study's public registry record.
Ligen Liu, MD · 18017337037 · liuligen@shsmu.edu.cn
Always discuss trial participation with your own doctor first.
| Beizhan Hospital | Shanghai, China | Not Yet Recruiting |
| Pla Navy Feature Medical Center | Shanghai, China | Not Yet Recruiting |
| Shanghai Ruijin Hospital | Shanghai, China | Not Yet Recruiting |
| Shanghai Tong Ren hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05736978